glp 1 vs semaglutide How New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment Story The patent expiry of semaglutide,

Were pleased to share results from an AI-based analysis showing a weekly 1.8 mg dose of our 1:1 glucagon/GLP-1 dual receptor agonist resulted in significant reductions in liver fibrosis in patients with MASH

When blood glucose levels rise after eating, these medications enhance insulin release while simultaneously suppressing glucagon secretion from alpha cells

Note: Listen to this updated July 2025 Paloma podcast that takes a deep dive into the issue of tariffs and the potential impact on your medications

Persistence with antidiabetic treatment has been shown to play an important role in glycaemic control, being associated not only with better clinical outcomes but also with economic benefits [8, 9]

[DOI] [PMC free article] [PubMed] [Google Scholar] 8.Rodrigues F., Teixeira D.S., Neiva H.P., Cid L., Monteiro D